Kewaunee Scientific Corporation (KEQU) exhibits 28.5% gross margins and 16.7% return on invested capital within Health Care (Medical Specialities), balanced against a 6.3x enterprise multiple and 4.8% implied options volatility.
Sustained 28.5% gross profitability converts into 5.9% operating margin and 16.7% ROIC, outpacing sector cost of capital.
ROIC: 16.7% // GM: 28.5%YoY revenue trajectory of +17.3% paired with 19.20% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +17.3% // FCF YLD: 19.20%Altman Z-Score of 3.37 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.37 // F-SCORE: 8/9Trading at 10.1x trailing P/E (8.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 10.1x // EV/EBITDA: 6.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $33.51 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend 3.4% net margins.
NET MARGIN: 3.4% // D/E: 0.23x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KEQU & activate live FRED threshold breach alerts.